These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28122078)

  • 1. Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants: A Review.
    Plitt A; McGuire DK; Giugliano RP
    JAMA Cardiol; 2017 Apr; 2(4):442-448. PubMed ID: 28122078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus.
    Fauchier L; Boriani G; de Groot JR; Kreutz R; Rossing P; Camm AJ
    Europace; 2021 Dec; 23(12):1873-1891. PubMed ID: 34411235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation.
    Bisson A; Angoulvant D; Philippart R; Clementy N; Babuty D; Fauchier L
    Adv Ther; 2017 Jun; 34(6):1283-1290. PubMed ID: 28493056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
    Lip GYH; Collet JP; Caterina R; Fauchier L; Lane DA; Larsen TB; Marin F; Morais J; Narasimhan C; Olshansky B; Pierard L; Potpara T; Sarrafzadegan N; Sliwa K; Varela G; Vilahur G; Weiss T; Boriani G; Rocca B;
    Europace; 2017 Nov; 19(11):1757-1758. PubMed ID: 29096024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial Fibrillation and Malignancy: The Clinical Performance of Non-Vitamin K Oral Anticoagulants-A Systematic Review.
    Russo V; Bottino R; Rago A; Micco PD; D' Onofrio A; Liccardo B; Golino P; Nigro G
    Semin Thromb Hemost; 2019 Mar; 45(2):205-214. PubMed ID: 30119139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation: An Updated Meta-analysis.
    Renda G; Ricci F; De Caterina R
    Am J Med; 2017 Apr; 130(4):457-461. PubMed ID: 27751896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current therapeutic strategies and future perspectives for the prevention of arterial thromboembolism: focus on atrial fibrillation.
    Potpara TS; Lip GY
    Curr Pharm Des; 2010; 16(31):3455-71. PubMed ID: 20858180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atrial Fibrillation and Stroke: Making Sense of Recent Observations on Anticoagulation.
    Proietti M; Lip GY
    Cardiol Clin; 2016 May; 34(2):317-28. PubMed ID: 27150180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel oral anticoagulants in non-valvular atrial fibrillation.
    Potpara TS; Lip GY
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):115-29. PubMed ID: 23953900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New pharmacologic approaches to prevent thromboembolism in patients with atrial fibrillation.
    Hammwöhner M; D'Alessandro A; Wolfram O; Goette A
    Curr Vasc Pharmacol; 2007 Jul; 5(3):211-9. PubMed ID: 17627564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence.
    Calabrò P; Gragnano F; Cesaro A; Marsico F; Pariggiano I; Patti G; Moscarella E; Cavallari I; Sardu C; Parato VM; Renda G; Niccoli G; Marcucci R; De Caterina R; ;
    Arch Cardiovasc Dis; 2020 Oct; 113(10):642-651. PubMed ID: 32712202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antithrombotic treatment of patients with valvular atrial fibrillation].
    Bovin A; Christensen TD; Grove EL
    Ugeskr Laeger; 2017 Jul; 179(29):. PubMed ID: 28789760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial fibrillation in athletes: From epidemiology to treatment in the novel oral anticoagulants era.
    Sanna GD; Gabrielli E; De Vito E; Nusdeo G; Prisco D; Parodi G
    J Cardiol; 2018 Oct; 72(4):269-276. PubMed ID: 29853275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants.
    Gallù M; Marrone G; Legramante JM; De Lorenzo A; Di Daniele N; Noce A
    Cardiovasc Ther; 2020; 2020():1743927. PubMed ID: 32684980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Atrial fibrillation and thromboembolic events prevention. State of the art].
    Matteoli S; Trappolini M; Chillotti FM
    Minerva Cardioangiol; 2001 Feb; 49(1):1-13. PubMed ID: 11279381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
    Renda G; di Nicola M; De Caterina R
    Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.